NASDAQ:CPIX - Cumberland Pharmaceuticals Stock Price, Forecast & News

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) posted its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.10. The specialty pharmaceutical company earned $10.37 million during the quarter, compared to analysts' expectations of $12.65 million. Cumberland Pharmaceuticals had a negative net margin of 10.13% and a positive return on equity of 6.76%. View Cumberland Pharmaceuticals' Earnings History.

Cumberland Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cumberland Pharmaceuticals.

1 equities research analysts have issued 1 year price targets for Cumberland Pharmaceuticals' shares. Their forecasts range from $9.75 to $9.75. On average, they anticipate Cumberland Pharmaceuticals' share price to reach $9.75 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View Analyst Price Targets for Cumberland Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cumberland Pharmaceuticals.

Press coverage about CPIX stock has been trending extremely negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cumberland Pharmaceuticals.

Cumberland Pharmaceuticals saw a decline in short interest in October. As of October 15th, there was short interest totalling 90,700 shares, a decline of 19.6% from the September 15th total of 112,800 shares. Based on an average daily volume of 27,200 shares, the days-to-cover ratio is currently 3.3 days. Currently, 1.0% of the shares of the company are short sold. View Cumberland Pharmaceuticals' Current Options Chain.

Some companies that are related to Cumberland Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include MacroGenics (MGNX), Amicus Therapeutics (FOLD), Galectin Therapeutics (GALT), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Protalix Biotherapeutics (PLX), AcelRx Pharmaceuticals (ACRX), Akari Therapeutics (AKTX), Allena Pharmaceuticals (ALNA) and Biocept (BIOC).

Cumberland Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (0.58%), Bailard Inc. (0.08%) and Financial Gravity Wealth Inc. (0.04%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, Caroline Young, Gordon R Bernard, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Institutional Ownership Trends for Cumberland Pharmaceuticals.

CPIX stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc.. View Insider Buying and Selling for Cumberland Pharmaceuticals.

CPIX stock was acquired by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co. and Financial Gravity Wealth Inc.. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals.

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CPIX stock can currently be purchased for approximately $5.16.

Cumberland Pharmaceuticals has a market capitalization of $78.35 million and generates $40.74 million in revenue each year. The specialty pharmaceutical company earns $-6,960,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. Cumberland Pharmaceuticals employs 80 workers across the globe.View Additional Information About Cumberland Pharmaceuticals.

The official website for Cumberland Pharmaceuticals is http://www.cumberlandpharma.com/.

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]